Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rankning i aktier #33959
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Aktiekurs
$17.15
Senast synkroniserad: 2026-08-03
Marknadsvärde
$6.51M
Förändring (1 dag)
9.80%
Förändring (1 år)
289.77%
Land
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategori

Antal utestående aktier för Galera Therapeutics, Inc. (GRTX)
Antal utestående aktier per March 2026: 98.62M
Enligt de senaste finansiella rapporterna och aktiekursen för Galera Therapeutics, Inc. är det aktuella antalet utestående aktier 98.62M. I slutet av December 2023 hade företaget 44.55M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Galera Therapeutics, Inc. (GRTX) från 2017 till 2026
Utestående aktier vid slutet av varje år
År Utestående aktier Ändra
2026 (TTM) 98.62M 80.52%
2024 54.63M 22.64%
2023 44.55M 64.47%
2022 27.09M 5.03%
2021 25.79M 3.70%
2020 24.87M 0.24%
2019 24.81M 28.15%
2018 19.36M -98.73%
2017 1.52B 0.00%
Utestående aktier för liknande företag eller konkurrenter
Företag Utestående aktier Skillnad Land
253.90M 157.45%
US
62.19M -36.95%
NL
- -
CH
- -
KR
0.00 -100.00%
BE